MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$249,700K
Net Income
$169,000K
Net Profit Margin
67.68%
EPS
$2.58
Unit: Thousand (K) dollars
Revenue Breakdown
Collaboration Agreement Revenue-...
License-Rigel Pharmaceuticals In...
Milestone Revenue-Vepdegestrant
Collaboration Agreement Revenue-...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
249,700
15,600
9,500
41,900
Cost of license revenue
9,000
-
-
-
Research and development
52,600
60,300
61,100
64,700
General and administrative
24,000
19,100
23,000
21,000
Total operating expenses
85,600
79,400
84,100
85,700
Income (loss) from operations
164,100
-63,800
-74,600
-43,800
Other expense, net
0
-100
-100
0
Interest income, net
5,500
6,400
7,400
9,000
Total other income
5,500
6,300
7,300
9,000
Net loss before income taxes and loss from equity method investment
-
-
-67,300*
-
Net income (loss) before income taxes
169,600
-57,500
-
-34,800
Income tax (expense) benefit
200
100
100
300
Loss from equity method investment
-
-
0*
-
Net income (loss)
169,400
-57,600
-67,400
-35,100
Unrealized gain on available-for-sale securities
-400
-1,600
-200
400
Comprehensive income (loss)
169,000
-59,200
-67,600
-34,700
Basic EPS
2.61
-0.9
-1.042
-0.48
Diluted EPS
2.58
-0.9
-1.045
-0.48
Basic Average Shares
64,800,000
64,000,000
64,900,000
73,200,000
Diluted Average Shares
65,700,000
64,000,000
64,700,000
73,200,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Collaboration Agreement
Revenue-Vepdegestrant
$133,700K
License-Rigel
Pharmaceuticals Inc.
$62,500K
Milestone
Revenue-Vepdegestrant
$50,000K
Collaboration Agreement
Revenue-Pfizer Inc.
$3,500K
Revenue
$249,700K
(1014.73%↑ Y/Y)
Interest income, net
$5,500K
(-46.60%↓ Y/Y)
Income (loss) from
operations
$164,100K
(329.51%↑ Y/Y)
Total other income
$5,500K
(-45.00%↓ Y/Y)
Total operating
expenses
$85,600K
(-8.84%↓ Y/Y)
Net income (loss)
before income taxes
$169,600K
(375.77%↑ Y/Y)
Research and development
$52,600K
(-23.32%↓ Y/Y)
General and
administrative
$24,000K
(-5.14%↓ Y/Y)
Cost of license
revenue
$9,000K
Net income (loss)
$169,400K
(376.80%↑ Y/Y)
Income tax (expense)
benefit
$200K
(166.67%↑ Y/Y)
Comprehensive income (loss)
$169,000K
(373.91%↑ Y/Y)
Unrealized gain on
available-for-sale securities
-$400K
(20.00%↑ Y/Y)
Buy us a coffee
ARVINAS, INC. (ARVN)
ARVINAS, INC. (ARVN)